• Shionogi will present new Phase 3 SCORPIO-PEP subpopulation data on ensitrelvir at IDWeek 2026 on Oct. 23.
• The analysis evaluates early pre-symptomatic use in exposed, PCR-positive household contacts, focusing on prevention-oriented outcomes rather than treatment.
• Additional presentations at the meeting cover real-world cefiderocol results in U.S. respiratory infections from the PROVE observational study.
• The update also flags recent portfolio milestones, including FDA clearance of XOCOVA and regulatory progress for pediatric use of Fetroja.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shionogi & Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609090830BIZWIRE_USPR_____20260909_BW212630) on September 09, 2026, and is solely responsible for the information contained therein.